ClinicalTrials.gg
RecruitingNCT05945212NEUROVIB-AVCUpdated Oct 9, 2026

Effects of Local Vibrations Program of Dorsiflexor Muscles on Neuromotor Recovery in Subacute Stroke Patients.

An interventional study of Vibration and Sham vibration in Stroke Rehabilitation, sponsored by Centre Hospitalier Universitaire de Saint Etienne. Recruiting at 7 sites in France. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-10-09.

Sponsored by Centre Hospitalier Universitaire de Saint Etienne · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Started Mar 2024; still recruiting 2 years 8 months later.
Updated Oct 9, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
70
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 18 studies in Stroke by Centre Hospitalier Universitaire de Saint Etienne — 4 open to participants now, 6 under way, none of them phase 3. Stroke · Centre Hospitalier Universitaire de Saint Etienne.

Planned enrollment
2nd of 13
70 · median 37
Started
2024
the only one that year
No phase
13 of 18
4 open now
Registered
14th of 18
by date

Among the 18 studies in Stroke by Centre Hospitalier Universitaire de Saint Etienne, this one is the 2nd largest by planned enrollment of the 13 interventional ones that give a count, is the only one that started in 2024, is one of 13 with no phase, and was the 14th registered.

Stroke

8,283 studies on the registry are indexed under Stroke; 2,065 are open to participants now.

Browse Stroke studies →

Open to participants now

4 of the 18 studies in Stroke by Centre Hospitalier Universitaire de Saint Etienne are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 1,418 Stroke studies recruiting now, 698 (49%) set no upper age limit and 281 (20%) stop at 75 or younger; 77 take children under 18; 197 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Stroke by Centre Hospitalier Universitaire de Saint Etienne, or all of them as a file.
02

Study summary

The aim of the vibration intervention proposed in the current study is to allow a better neuromotor recovery in subacute stroke patients when compared with standard rehabilitation alone. These last years, it has been proven that the solicitation of a muscle using vibrations may lead to positive effects on the neuromuscular function. Thus, the aim of the current study is to assess if the addition to a standard rehabilitation program of local vibrations sessions of the dorsiflexor muscles of the paretic limb of stroke patients may allow a better recovery of walking speed (primary outcome). One group using vibrations (i.e. experimental group) and one group with sham vibration (i.e. control group) will take part to this study.

03

Conditions studied

  • Stroke Rehabilitation

Browse trials for

Keywords

  • Local vibration
  • Stroke
  • Motor recovery
  • Walking speed
  • Gait
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Stroke patients in subacute rehabilitation phase (between 14 days and 3 months post-stroke)
  • Presenting with a stroke, ischemic or hemorrhagic
  • Lower-limb deficiency with an initial motor testing \< 4 according to the MRC scale
  • No neurological history with functional impact other than stroke
  • Having received informed information about the study and having signed the written consent
  • Affiliated or entitled to a social security scheme.
  • Patients under guardianship may be included; they may give their consent with the assistance of their guardian.

If the participant is unable to write, their consent may be given and documented by other appropriate means in the presence of at least one impartial witness. In this case, the witness will sign and date the document.

Exclusion criteria

Exclusion Criteria:

  • Multiple stroke
  • Other neurological, cognitive or psychiatric conditions
  • Orthopedic ankle history compromising measurements
  • Botulinum toxin injected in the lower limb prior the study protocol
  • Patient with phlebitis or risk of thrombosis in the lower limb
  • Patient under tutorship
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
70 participants (estimated)

Study arms

  • Experimental
    Vibration

    Stroke patients in subacute rehabilitation phase will be included. In addition of a subacute post-stroke standard rehabilitation program, they will have a vibration program.

    Device: Vibration · Other: 10 meters Walk Test · Other: 2 Minute Walk Test (2MWT) · Other: Fugl-Meyer (FMA-LE) · Other: Modified Ashworth scale · Other: ABILOCO questionnaire · Other: Barthel index · Other: isometric ergometer · Other: Electromyograms (EMG) · Other: Traditional quantified gait analysis · Other: SPM - Statistical Parametric Mapping · Other: FACIT questionnaire (Functional Assessment of Chronic Illness Therapy)

  • Sham comparator
    no vibration

    In addition of a subacute post-stroke standard rehabilitation program, they will have a sham vibration program.

    Device: Sham vibration · Other: 10 meters Walk Test · Other: 2 Minute Walk Test (2MWT) · Other: Fugl-Meyer (FMA-LE) · Other: Modified Ashworth scale · Other: ABILOCO questionnaire · Other: Barthel index · Other: isometric ergometer · Other: Electromyograms (EMG) · Other: Traditional quantified gait analysis · Other: SPM - Statistical Parametric Mapping · Other: FACIT questionnaire (Functional Assessment of Chronic Illness Therapy)

Interventions

  • DeviceVibration

    The program will take place over 40 sessions : 5 sessions per week, for 2 months (40 sessions in total over 8 weeks during the hospitalization in the department); this group will benefit from an effective vibration of a frequency of 100Hz

    Also known as: VIBRAMOOV PHYSIO

  • DeviceSham vibration

    The program will take place over 40 sessions: 5 sessions per week, for 2 months (40 sessions in total over 8 weeks during hospitalization in the department); this group will not benefit from effective vibration.

  • Other10 meters Walk Test

    Short-distance ambulation speed is measurement between 2 markers on the ground 10 meters apart in a corridor with flat ground, the patient starting his walk 3 meters before to have a launched march disregarding markers, and ends 3 meters After. The stopwatch is started when the markers are crossed.

  • Other2 Minute Walk Test (2MWT)

    Long-distance ambulation speed is measured from a standing start and the test involves asking the patient to walk as far as possible in 2 minutes.

  • OtherFugl-Meyer (FMA-LE)

    The Fugl-Meyer (FMA-LE) assessment of motor skills : measurement of the intensity of reflexes, as well as an assessment of voluntary movements and motor coordination. Score from 0 to 34

  • OtherModified Ashworth scale

    The modified Ashworth scale allows the measurement of spasticity, that is to say the measurement of muscle tone by mobilizing the segment of the lower limb and by evaluating the resistance to stretching of the muscles. Score from 0 to 4

  • OtherABILOCO questionnaire

    The ABILOCO questionnaire evaluate the autonomy in the walking capacities of the patients (13-items)

  • OtherBarthel index

    The Barthel index measure autonomy in daily life.

  • Otherisometric ergometer

    Evaluate voluntary maximum force in isometric ankle dorsiflexion by Cybex isometric ergometer results.

    Also known as: Cybex isometric ergometer (Henley Healthcare, Sugarland, TX, USA)

  • OtherElectromyograms (EMG)

    Assessment of neuromuscular fatigue by electromyograms (EMG). Surface electrodes is place on the tibial muscle anterior to non-invasively collect electromyograms (EMG). The intensity of stimulation will be gradually increased until a plateau in mechanical (strength) and electromyograms (EMG) responses is obtained.

    Also known as: Electrodes Meditrace 100, Covidien, Mansfield, MA

  • OtherTraditional quantified gait analysis

    Gait kinematics will be recorded on a force platform (90 x 90 cm, Model 9287C, Kistler, Winterthur, Switzerland) to determine: joint angles, net joint moments and powers at the ankle, knee and hip.

    Also known as: 0D

  • OtherSPM - Statistical Parametric Mapping

    Addition of a temporal component to the traditional quantified gait analysis, allowing the focus to be on time series parameters.

    Also known as: 1D

  • OtherFACIT questionnaire (Functional Assessment of Chronic Illness Therapy)

    A short questionnaire consisting of 13 questions to which the patient answers on a scale from 0 to 4. The scores are simply added up, inverting the scale for negative sentences, to give a result out of 52 points. The lower the score, the greater the fatigue.

06

What researchers measure

Primary outcomes

  1. Gait speed by 10 meters Walk Test (in meter /second) results

    Analysis Gait speed by 10 meters Walk Test (in meter /second) results

    Time frame: Month 2

Secondary outcomes

  1. Walking performance by 10 meters Walk Test (in meter /second) results

    Analysis Walking performance (comfort speed) by 10 meters Walk Test (in meter /second) results

    Time frame: Month 0, 1, 2, 3, 4

  2. Walking performance by 2 Minute Walk Test (2MWT) (in meter) results

    Analysis Walking performance (distance) by 2 Minute Walk Test (2MWT) (in meter) results

    Time frame: Month 0, 1, 2, 3, 4

  3. Walking performance by Quantified Gait Analysis results

    Walking performance will be assessed using: (in m/s) in the 10-meter test (short distance), distance (in m) covered in a 2-minute walk test (long distance) , and qualitatively by a Quantified Gait Analysis (performed only in M2 and M4).

    Time frame: Month 2, 4

  4. Motor function of the paretic lower limb

    The motor function of the paretic lower limb will be measured by the Fugl Meyer Assessment scale for lower limbs (FMA-LE) which includes five domains: Motor skills; Balance skills; Sensitivity; Range of motion; Joint pain. A three-point ordinal scale (0: cannot perform; 1: partially performed; 2: fully performed) is applied to each item. The maximum score is 226.

    Time frame: Month 4

  5. Lower limb spasticity level

    The level of spasticity of the lower limb will be measured by the modified Ashworth scale : a 6-point scale with scores ranging from 0 to 4, where the lowest scores represent normal muscle tone and the highest scores represent spasticity or increased resistance to passive movement.

    Time frame: Month 4

  6. Autonomy in walking activities

    The patient's autonomy in walking activities will be measured by the ABILOCO questionnaire and in daily living activities by the Barthel index.

    Time frame: Month 4

  7. Lower limb strength

    Lower extremity strength will be measured as maximal voluntary strength in isometric ankle dorsiflexion.

    Time frame: Month 4

  8. Neuromuscular fatigue (1)

    Neuromuscular fatigue will be assessed by the level of voluntary activation (in %).

    Time frame: Month 4

  9. Neuromuscular fatigue (2)

    Neuromuscular fatigue will be assessed by corticospinal and intracortical excitability thanks to electromyographic responses evoked by transcranial magnetic stimulation.

    Time frame: Month 4

  10. Neuromuscular fatigue (3)

    Neuromuscular fatigue will be assessed by spinal excitability thanks to electromyographic responses evoked by electrical nerve stimulation.

    Time frame: Month 4

  11. Neuromuscular fatigue (4)

    Neuromuscular fatigue will be assessed by perceived subjective fatigue measured by the FACIT questionnaire : the Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System is a collection of health-related quality of life (HRQOL) questionnaires targeted to the management of chronic illness, including over 400 questions. Higher scores for the scales and subscales indicate better quality of life.

    Time frame: Month 4

07

Study locations

2 of 7 sites recruiting
  • Centre Hospitalier Georges Claudinon
    Le Chambon-Feugerolles, 42500, France
    Not yet recruiting
    • Thibault TRAMOY, MD · Contact
    • Thibault TRAMOY, MD · Principal investigator
  • Hôpital Marrel
    Rive-de-Gier, 42800, France
    Recruiting
    • Kevin STAMPONE, MD · Contact
    • Kevin STAMPONE, MD · Principal investigator
  • Centre Hospitalier de Roanne
    Roanne, 42300, France
    Not yet recruiting
    • Annelise MOULINET, MD · Principal investigator
  • Service de SSR Val-Rosay
    Saint-Didier-au-Mont-d'Or, 69370, France
    Not yet recruiting
    • Julie DI MARCO, MD · Contact
    • Julie DI MARCO, MD · Principal investigator
  • Hôpital Bellevue, CHU de Saint-etienne
    Saint-Etienne, 42100, France
    Recruiting
    • Bruno FERNANDEZ, MD · Contact
    • Bruno FERNANDEZ, MD · Principal investigator
    • Pascal GIRAUX, MD PhP · Sub investigator
    • Julia TOULY, MD · Sub investigator
    • Etienne OJARDIAS, MD · Sub investigator
    • Hugo BESSAGUET, MD · Sub investigator
  • Service de SSR du Centre Le Clos Champirol
    Saint-Etienne, 42270, France
    Not yet recruiting
    • Alexandre BERTHOLON, MD · Contact
    • Alexandre BERTHOLON, MD · Principal investigator
  • Hospices Civils de Lyon, site Henry Gabrielle
    Saint-Genis-Laval, 69230, France
    Not yet recruiting
    • Sophie JACQUIN COURTOIS, MD PhD · Contact
    • Sophie JACQUIN COURTOIS, MD PhD · Principal investigator
    • Laure HUCHON, MD · Sub investigator
08

References and documents

Publications

  • Bessaguet H, Fernandez B, Malejac V, Nerriere E, Velarde M, Coiffet A, Rimaud D, Lapole T. Effect of tibialis anterior focal muscle vibration for gait rehabilitation in hemiplegic individuals during the subacute phase after stroke: the NEUROVIB-AVC study protocol - a multicentric randomised controlled trial. BMJ Open. 2025 May 6;15(5):e102838. doi: 10.1136/bmjopen-2025-102838. PubMed 40335131 ↗

Individual participant data

Plan to share: Yes — Data shared: Individual participant data that underlie the results reported in the article, after deidentification (text, tables, figures, and appendices)

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: Beginning 3 months and ending 5 years following article publication

Access criteria: Researchers who provide a methodologically sound proposal To achieve aims in the approved proposal Proposals should be directed to corresponding author. To gain access, data requestors will need to sign a data access agreement.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2024 (actual). Primary completion is estimated for Dec 2028, 57 months after the start.

Of 3,121 non-industry interventional studies with no phase under Stroke, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 46. This study's planned 57 months is above that.

Counting every sponsor, half of 3,265 studies reached it within 23 months; a quarter within 10 and three quarters within 46.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 9, 2026: primary completion Jan 2027 → Dec 2028 and completion May 2027 → May 2029.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 6, 2023
First posted
Jul 14, 2023
StartActual
Mar 12, 2024
Primary completionEst.
Dec 31, 2028was Jan 2027
CompletionEst.
May 7, 2029was May 2027
Last update
Oct 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Jan 7, 2027→Dec 31, 2028
Oct 9, 2026
Study completion
May 15, 2027→May 7, 2029
Oct 9, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Hôpital Marrel · Rive-de-Gier, FranceContact person changed (no phone or email listed)Contact person changed (no phone or email listed)Contact removed (no phone or email listed)
Oct 9, 2026
Show all 1 update
  1. Oct 9, 2026
    Primary completion Jan 7, 2027→Dec 31, 2028
    Study completion May 15, 2027→May 7, 2029
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Hôpital Marrel · Rive-de-Gier, FranceContact person changed (no phone or email listed)Contact person changed (no phone or email listed)Contact removed (no phone or email listed)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05945212
Collaborators
Ministry of Health, France
Responsible party
Sponsor
First posted
Jul 14, 2023
Start date
Mar 12, 2024
Primary completion
Dec 31, 2028 (estimated)
Completion
May 7, 2029 (estimated)
Last update
Oct 9, 2026

Study contacts

Bruno FERNANDEZ, MD
Contact
bruno.fernandez@chu-st-etienne.fr
(0)477120638 ext. +33
Bruno FERNANDEZ, MD
principal investigator · Centre Hospitalier Universitaire de Saint Etienne

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion